Home » Posts tagged with » Australia
VirTrial to help BetterLife Pharma in launching COVID-19 clinical trials

VirTrial to help BetterLife Pharma in launching COVID-19 clinical trials

VirTrial, a US bioscience technology company, has been selected by Canadian biotech company BetterLife Pharma as its telehealth platform provider of choice for launching COVID-19 clinical trials. The partnership will help BetterLife Pharma to carry out remote patient monitoring for its upcoming COVID-19 clinical trials in Australia for evaluating the efficacy of its interferon alpha 2b formulation […]

Noxopharm doses first patient in NOXCOVID-1 clinical trial with Veyonda

Australian drug development company Noxopharm has dosed the first patient in the phase 1 NOXCOVID-1 clinical trial with Veyonda, its lead pipeline candidate, in hospitalized COVID-19 patients. Veyonda is an experimental anti-cancer drug. It is being evaluated in the NOXCOVID-1 clinical trial in the treatment of hospitalized patients with moderate lung dysfunction, who need low […]

Continue reading …
Kazia Therapeutics gets US RPDD for paxalisib in childhood brain cancer

Kazia Therapeutics, an Australian biotech company, has secured the rare pediatric disease designation (RPDD) for paxalisib (formerly GDC-0084) from the US Food and Drug Administration (FDA) for the treatment of diffuse intrinsic pontine glioma (DIPG). Diffuse intrinsic pontine glioma is considered to be a rare and highly-aggressive childhood brain cancer. The rare pediatric disease designation […]

Continue reading …
Noxopharm launches NOXCOVID-1 clinical trial of Veyonda across Europe

Noxopharm, an Australian clinical-stage pharma company, has started the phase 1 NOXCOVID-1 clinical trial for Veyonda in Europe to evaluate the anti-cancer drug candidate as a potential treatment for cytokine storm and septic shock in COVID-19 patients. With a capability to inhibit cGAS-STING signalling, Veyonda can potentially block the start of the cytokine storm which […]

Continue reading …
Australian clinical diagnostics company SpeeDx raises $15m in Series B round

SpeeDx, an Australian clinical diagnostics company, to support improved patient outcomes, has secured $15 million in a Series B funding round from US-based investor Northpond Ventures. The company has developed a molecular diagnostics test portfolio, mainly for infectious diseases, that offers identification and also therapeutic guidance capabilities. Michael P. Rubin – Founder and CEO of […]

Continue reading …
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]

Continue reading …
Levo gets FDA fast track status for LV-101 in Prader-Willi syndrome

US biotech company Levo Therapeutics has been granted fast track designation for LV-101 (intranasal carbetocin) from the US Food and Drug Administration (FDA) for the treatment of Prader-Willi syndrome (PWS). According to the US National Library of Medicine, Prader-Willi syndrome is a complex genetic condition that impacts several parts of the body. In infancy, Prader-Willi […]

Continue reading …
CMD enrolls first patient in placebo-controlled ALS trial of CuATSM

Collaborative Medicinal Development (CMD) has enrolled the first patient in a placebo-controlled clinical trial to evaluate the safety and efficacy of CuATSM in patients with Amyotrophic Lateral Sclerosis (ALS). The Australian biotech company plans to enroll a total of 80 patients across four clinical sites in Australia. Amyotrophic Lateral Sclerosis is also known as Motor […]

Continue reading …
Prana Biotechnology secures orphan designation for PBT434 in MSA

Australian biotech company Prana Biotechnology has secured Orphan Drug designation for PBT434, its lead molecule, for the treatment of Multiple System Atrophy (MSA). Prana Biotechnology claims that its application was based on the proposed use of the molecule as a treatment for MSA, including the medical and scientific rationale. The Australian biotech company said that […]

Continue reading …
Research finds aspirin intake does not reduce heart attack or stroke risk

A seven-year study held in more than 19,000 older people from the US and Australia found that daily intake of aspirin daily does not cut down the chances of heart attack or stroke and neither does it have any benefit in prolonging life free of disability. The study was headed by Monash University in Australia […]

Continue reading …